CryoCell International Inc (CCEL)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • AMEX
Market Cap: $36.69M
Last updated: Nov 17, 2026 at 4:10 PM ET
CryoCell International Inc (CCEL) Statistics
CryoCell International (CCEL) has a market cap of $36.69M and an enterprise value of $44.37M. It earned -$1.95M on revenue of $31.13M over the last 12 months.
Total Valuation
Enterprise value is 20.96% above the market cap, as debt exceeds cash.
| Market Cap | $36.69M |
|---|---|
| Enterprise Value | $44.37M |
| Latest price (Nov 17, 2026) | $4.62 |
Key Dates
The next earnings report is expected on Feb 25, 2027, covering the quarter ending Nov 30, 2026.
| Next Earnings Date | Feb 25, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 9, 2026 |
| Fiscal Year End | November |
Valuation Ratios
The price to sales ratio is 1.2x. Its year-end P/S ranged from 0.9x to 3.2x from 2016 to 2025.
| Forward P/E | 56.6x |
|---|---|
| P/S Ratio | 1.2x |
| Forward P/S | 1.2x |
| P/FCF Ratio | 8.0x |
| P/OCF Ratio | 7.5x |
Enterprise Valuation
Counting debt and cash, the company is valued at 34.9x EBITDA and 9.7x free cash flow.
| EV / Sales | 1.4x |
|---|---|
| EV / EBITDA | 34.9x |
| EV / FCF | 9.7x |
Price Statistics
The stock is up 12.41% over 52 weeks and trades 3.13% above its 50-day average.
| Beta (1Y) | 0.56 |
|---|---|
| 52-Week Change | +12.41% |
| 1-Month Change | -0.65% |
| 3-Month Change | +13.51% |
| 6-Month Change | +31.62% |
| 5-Year Change | -58.49% |
| 10-Year Change | +27.07% |
| Total Return (1Y) | +12.41% |
| Total Return (3Y CAGR) | +5.01% |
| Total Return (5Y CAGR) | -14.38% |
| Return vs SPY (1Y) | +1.68% |
| Max Drawdown (1Y) | -35.00% |
| Max Drawdown (3Y) | -66.25% |
| Sharpe Ratio (1Y) | 0.16 |
| Correlation with SPY (1Y) | 0.10 |
| 50-Day Average | $4.48 |
| 200-Day Average | $3.77 |
| 52-Week Range | $2.72 to $5.45 |
| RSI (14 Days) | 47.0 |
| Average Volume (20 Days) | 9.92K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.86x current liabilities.
| Current Ratio | 0.86x |
|---|---|
| Quick Ratio | 0.82x |
| Debt / EBITDA | 7.09x |
| Debt / FCF | 1.96x |
| Interest Coverage | 2.50x |
Returns and Efficiency
Return on invested capital is 1.15% over the last 12 months, against a 5-year average of 351.04%.
| Return on Assets (ROA) | -3.12% |
|---|---|
| Return on Invested Capital (ROIC) | 1.15% |
| Return on Capital Employed (ROCE) | -0.18% |
| ROA (5Y Average) | -2.23% |
| ROIC (5Y Average) | 351.04% |
| Asset Turnover | 0.50x |
| Inventory Turnover | 15.84x |
| Receivables Turnover | 4.53x |
| Cash Conversion Cycle | -40 days |
Scores
CCEL has an Altman Z-Score of -0.08, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.08 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $31.13M over the last 12 months is down 1.96% from the 12 months before.
| Revenue | $31.13M |
|---|---|
| Revenue Growth (YoY) | -1.96% |
| Gross Profit | $24.45M |
| Operating Income | $189.42K |
| Pretax Income | -$1.91M |
| Net Income | -$1.95M |
| EBITDA | $1.29M |
| EBIT | -$83.55K |
| Reported EPS (TTM) | -$0.22 |
Trailing 12 months through Aug 31, 2026.
Balance Sheet
| Cash and Equivalents | $1.43M |
|---|---|
| Total Debt | $9.11M |
| Net Debt | $7.69M |
| Net Debt Per Share | $0.95 |
| Working Capital | -$2.16M |
| Shareholder Equity | -$16.39M |
| Tangible Book Value | -$19.17M |
| Total Assets | $62.30M |
| Total Liabilities | $78.70M |
Balance sheet as of Aug 31, 2026.
Cash Flow
After $268.87K of capital spending, operating cash flow left $4.65M of free cash flow.
| Operating Cash Flow | $4.92M |
|---|---|
| Capital Expenditures | $268.87K |
| Free Cash Flow | $4.65M |
| FCF Per Share | $0.58 |
| Depreciation and Amortization | $1.37M |
Trailing 12 months through Aug 31, 2026.
Margins
The operating margin is 0.61%, against a 5-year average of 0.07%.
| Gross Margin | 78.54% |
|---|---|
| Operating Margin | 0.61% |
| Pretax Margin | -6.13% |
| Net Margin | -6.25% |
| EBITDA Margin | 4.13% |
| EBIT Margin | -0.27% |
| FCF Margin | 14.94% |
| Gross Margin (5Y Average) | 72.98% |
| Operating Margin (5Y Average) | 0.07% |
| Net Margin (5Y Average) | -4.09% |
Growth
Revenue grew 1.33% a year over 3 years.
| Revenue Growth (3Y CAGR) | +1.33% |
|---|---|
| Revenue Growth (5Y CAGR) | +0.27% |
| FCF Growth (5Y CAGR) | -8.91% |
| Operating Income Growth (3Y CAGR) | -50.69% |
Dividends and Yields
CCEL does not pay a dividend. Its free cash flow yield is 12.49%.
| FCF Yield | 12.49% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 5 similar companies, CCEL has the 5th highest P/S.
P/S RatioPeer median 83.5x
ROICPeer median -63.93%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -55.27%
| P/S Ratio | 1.2x vs 83.5x median |
|---|---|
| ROIC | 1.15% vs -63.93% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -1.96% vs -55.27% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CCEL
What is CCEL's market cap?
CryoCell International has a market cap of $36.69M. Its enterprise value, which adds debt and subtracts cash, is $44.37M.
How many shares of CCEL are outstanding?
CryoCell International has 8.06M shares outstanding. The count is up 0.06% from a year earlier.
Does CCEL pay a dividend?
No. CryoCell International does not pay a dividend.
How much debt does CCEL have?
CryoCell International has $9.11M of total debt and $1.43M of cash and equivalents, a net debt position of $7.69M.
CCEL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors